Search Results - "Burge, Russel"

CED Reviewers January 2023–December 2023.

Source: Clinical & Experimental Dermatology. Apr2024, Vol. 49 Issue 4, p445-448. 4p.

Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom.

Authors: Pierce, Evangeline J. Burge, Russel T. Hirst, Alex J. et al.

Source: Dermatology & Therapy. May2024, Vol. 14 Issue 5, p1103-1114. 12p.

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program.

Authors: Gottlieb, Alice B. Burge, Russel Malatestinic, William N. et al.

Source: Dermatology & Therapy. Aug2023, Vol. 13 Issue 8, p1831-1846. 16p.

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.

Authors: Blauvelt, Andrew Burge, Russel Gallo, Gaia et al.

Source: Dermatology & Therapy. Mar2022, Vol. 12 Issue 3, p701-714. 14p.

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Authors: Blauvelt, Andrew Kircik, Leon Schlesinger, Todd et al.

Source: Journal of Dermatological Treatment. Dec2025, Vol. 36 Issue 1, p1-9. 9p.

Genital Psoriasis: An Updated Review of Diagnosis and Management for Healthcare Providers.

Authors: Guenther, Lyn C. Cather, Jennifer C. Gooderham, Melinda J. et al.

Source: Dermatologic Therapy. 7/11/2026, Vol. 2026, p1-21. 21p.

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.

Authors: Langley, Richard G. B. Reich, Kristian Strand, Vibeke et al.

Source: Quality of Life Research. Feb2020, Vol. 29 Issue 2, p369-380. 12p. 6 Charts, 2 Graphs.

Subjects: Psoriasis, Quality of life

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.

Authors: Egeberg, Alexander Hawkes, Jason E. Somani, Najwa et al.

Source: Dermatology & Therapy. Apr2024, Vol. 14 Issue 4, p1007-1018. 12p.

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry.

Authors: Yu, Chen Wang, Gang Burge, Russel T. et al.

Source: Dermatology & Therapy. Jan2023, Vol. 13 Issue 1, p187-206. 20p.

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.

Authors: Blauvelt, Andrew Shi, Nianwen Burge, Russel et al.

Source: Dermatology & Therapy. Dec2021, Vol. 11 Issue 6, p2133-2145. 13p.

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.

Authors: Warren, Richard B. See, Kyoungah Burge, Russel et al.

Source: Dermatology & Therapy. 2021, Vol. 11 Issue 1, p73-86. 14p.

Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J).

Authors: Honma, Masaru Cai, Zhihong Burge, Russel et al.

Source: Dermatology & Therapy. Dec2020, Vol. 10 Issue 6, p1397-1404. 8p.

Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.

Authors: Blauvelt, Andrew Shi, Nianwen Somani, Najwa et al.

Source: Clinical Drug Investigation. Mar2023, Vol. 43 Issue 3, p185-196.

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.

Authors: Elewski, Boni E. Blauvelt, Andrew Gallo, Gaia et al.

Source: Dermatology & Therapy. Apr2022, Vol. 12 Issue 4, p911-920. 10p.

Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.

Authors: Blauvelt, Andrew Lomaga, Mark Burge, Russel et al.

Source: Journal of Dermatological Treatment. Mar2020, Vol. 31 Issue 2, p141-146. 6p.

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab.

Authors: Blauvelt, Andrew Shi, Nianwen Burge, Russel et al.

Source: Patient Preference & Adherence. Mar2020, Vol. 14, p517-527. 11p.

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q).

Authors: Soung, Jennifer Cather, Jennifer C. Gooderham, Melinda et al.

Source: JEADV Clinical Practice. Jun2023, Vol. 2 Issue 2, p282-292. 11p.

Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program.

Authors: Gulliver, Wayne Gooderham, Melinda J. Zhu, Baojin et al.

Source: Dermatology & Therapy. Jan2023, Vol. 13 Issue 1, p235-244. 10p.

Disease response and patient-reported outcomes among initiators of ixekizumab.

Authors: Shahriari, Mona Harrison, Ryan W. Burge, Russel et al.

Source: Journal of Dermatological Treatment. May2022, Vol. 33 Issue 3, p1538-1546. 9p.

Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.

Authors: Blauvelt, Andrew Gooderham, Melinda Griffiths, Christopher E. M. et al.

Source: Dermatology & Therapy. Mar2022, Vol. 12 Issue 3, p727-740. 14p.